Phase 1 study comprised of open-label, dose escalation and expansion cohort study of P-CD19CD20-ALLO1 allogeneic T stem cell memory (Tscm) CAR-T cells in subjects with relapsed/refractory B cell malignancies
Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High-grade B-cell Lymphoma, Primary Mediastinal Large B-cell Lymphoma (PMBCL), Transformed Follicular Lymphoma (tFL), Follicular Lymphoma Grade 3B
Phase 1 study comprised of open-label, dose escalation and expansion cohort study of P-CD19CD20-ALLO1 allogeneic T stem cell memory (Tscm) CAR-T cells in subjects with relapsed/refractory B cell malignancies
P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies
-
University of California San Diego, La Jolla, California, United States, 92093
Loma Linda University Cancer Center, Loma Linda, California, United States, 92354
Wayne State - Karmanos Cancer Institute, Detroit, Michigan, United States, 48201
UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States, 27599
University of Cincinnati, Cincinnati, Ohio, United States, 45206
University of Oklahoma, Health Sciences Center, Oklahoma City, Oklahoma, United States, 73104
Prisma Health - Upstate Cancer Institute, Greenville, South Carolina, United States, 29605
Vanderbilt University Medical Center, Nashville, Tennessee, United States, 37232
Baylor Scott & White Research Institute, Dallas, Texas, United States, 75204
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to
ALL
No
Poseida Therapeutics, Inc.,
Rajesh Belani, MD, STUDY_DIRECTOR, Vice President, Clinical Development
2041-03